<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468712</url>
  </required_header>
  <id_info>
    <org_study_id>CLASS-03a</org_study_id>
    <nct_id>NCT03468712</nct_id>
  </id_info>
  <brief_title>Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers</brief_title>
  <acronym>CLASS-03a</acronym>
  <official_title>Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers: A Prospective Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer is the third major cancer of global cancer-related death. In China, the early
      diagnosis rate of gastric cancer is relatively low, and most patients are with locally
      advanced tumor stage. The neoadjuvant chemotherapy (NAC) can bring the survival advantage for
      gastric cancer patients with locally advanced tumor stage. The primary goal of NAC is to
      control the micrometastasis and/or progression of the primary lesion in order to improve
      potential of radical gastrectomy. NAC is recommended for patients with locally advanced stage
      (T2-4Nx) according to the latest NCCN Gastric Cancer Guidelines.

      Laparoscopy distal gastrectomy (LDG) can achieve a better postoperative short-term recovery
      than the traditional open distal gastrectomy (ODG), which can reduce the intraoperative blood
      loss and to shorten the postoperative hospital stay. Therefore, Enhanced Recovery After
      Surgery program of gastric cancer surgery recommends the use of minimally invasive surgery.
      For long-term survival outcomes, there is limited evidence supported that laparoscopic
      gastrectomy is comparable open gastrectomy. Therefore, due to the lack of high-quality
      prospective clinical trial results, whether advanced tumor is suitable for laparoscopic
      surgery is still controversial. Therefore, some multi-center prospective randomized
      controlled trials have been carried out, compared safety and long-term survival outcome
      between laparoscopic and open gastrectomy in locally advanced gastric cancer patients.
      CLASS-01 trials reported that for locally advanced gastric cancers, laparoscopic D2 distal
      gastrectomy is safe and feasible.

      Patient's surgical tolerance and stress response may be inhibited after the treatment of NAC.
      The aim of this trial is to confirm the safety of laparoscopy distal D2 radical gastrectomy
      for the treatment of after neoadjuvant chemotherapy gastric cancer patients (cT3-4a, N+, M0)
      in terms of postoperative complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-centers, open-label, single-arm study, and the aim of this trial
      is to evaluate the safety of laparoscopic distal D2 radical gastrectomy for the treatment of
      locally advanced gastric cancer (cT3-4a, N+, M0) after neoadjuvant chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative overall morbidity rate</measure>
    <time_frame>Postoperative 30 days</time_frame>
    <description>The proportion value will be calculated by the number of patients with any operative complication as the numerator and the number of patients undergoing surgical treatment as the denominator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality rate</measure>
    <time_frame>Postoperative 30 days</time_frame>
    <description>Mortality will be calculated as the ratio between the number of patients who died as numerator and number of all patients undergoing surgical treatment as the denominator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>The day of surgery</time_frame>
    <description>Number of patients underwent gastrectomy for the denominator, number of R0 resection patients is numerator, the ratio is the R0 resection rate. The definition of R0 resection is according to the Japanese gastric cancer treatment guidelines 2014 (ver. 4)（Gastric Cancer. 2017 Jan;20(1):1-19.）.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion rate of laparoscopic surgery</measure>
    <time_frame>The day of surgery</time_frame>
    <description>Ratio will be calculated with the number of patients complete the laparoscopic gastrectomy as the numerator, and number of all patients undergoing laparoscopic surgical treatment as the denominator.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Complications, Postoperative</condition>
  <condition>Surgery--Complications</condition>
  <condition>Cancer of Stomach</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic D2 distal gastrectomy</intervention_name>
    <description>Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First Round Inclusion Criteria

               1. Age from over 18 to under 75 years;

               2. Primary gastric adenocarcinoma (including pap, tub, muc, sig, and por) confirmed
                  pathologically by endoscopic biopsy;

               3. cT3-4a, N+, M0 according to the AJCC 8th Cancer Staging Manual;

               4. Without peritoneal metastasis (examined by laparoscopic examination);

               5. Radical resection (R0) through distal subtotal gastrectomy with D2
                  lymphadenectomy is anticipated;

               6. Performance status 0 or 1 (Eastern Cooperative Oncology Group) ;

               7. ASA (American Society of Anesthesiology) score ≤ 3;

               8. Normal hemodynamic indices:

               1. Blood cell count: HB ≥ 90g/L, ANC ≥ 1.5×109/L, PLT ≥ 80×109/L;

               2. Liver and renal function: BIL＜1.5 times of the upper limit of normal reference
                  values, ALT and AST＜2.5 times of the upper limit of normal reference values, and
                  Crea≤1 time of upper limits of normal reference values.

          -  Second Round Inclusion Criteria

               1. Therapeutic response rating after neoadjuvant chemotherapy is CR, PR, SD, or
                  Therapeutic response rating after neoadjuvant chemotherapy is PD, tumor is
                  expected to have radical resection;

               2. Subjects are still willing to continue participating in this clinical trial.

        Exclusion Criteria:

          -  First Round Exclusion Criteria

               1. History of upper abdominal surgery (include endoscopic mucosal resection or
                  endoscopic submucosal dissection, except for laparoscopic cholecystectomy);

               2. History of acute pancreatitis;

               3. Enlarged or bulky regional lymph node (diameter＞3cm) by imaging exam;

               4. Patients have received neoadjuvant therapy prior to screen work;

               5. History of other malignant disease within the past five years;

               6. History of cerebrovascular accident within the past six months;

               7. History of continuous systematic administration of corticosteroids within the
                  past month;

               8. Scheduled simultaneous surgery for other disease;

               9. Emergency surgery due to complication (bleeding, obstruction or perforation)
                  caused by gastric cancer;

              10. Pyloric obstruction;

              11. FEV1＜50% of predicted value;

              12. Women who are pregnant or lactating at the time of screening;

              13. Severe mental disorder;

              14. Participating in other clinical studies;

              15. Refused to sign the informed consent;

          -  Second Round Exclusion Criteria

               1. Therapeutic response rating after neoadjuvant chemotherapy is PD, involvement of
                  adjacent structures(T4b), distal metastasis(M1), or enlarged or bulky regional
                  lymph node (diameter＞3cm) by preoperative imaging

               2. Patients cannot complete 3 cycles of chemotherapy due to intolerance;

               3. After 3 cycles of neoadjuvant chemotherapy, patients cannot tolerate surgery due
                  to severe adverse reactions, or ASA score ≥ 4 ;

               4. Patients undertake emergency operation due to tumor bleeding, perforation or
                  obstruction during chemotherapy;

               5. After signing the informed consent, the patient withdraws from this clinical
                  trial.

        Withdrawal Criteria After Second Round:

          1. Intro-abdominal metastasis of primary cancer is revealed intraoperatively;

          2. Primary cancer is confirmed to be un-resectable intraoperatively.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian-Kun Hu, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian-Kun Hu, M.D. Ph.D.</last_name>
    <phone>02885422878</phone>
    <email>hujkwch@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei-Han Zhang, M.D. Ph.D.</last_name>
    <phone>02885422480</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Cancer Hospital and Institute</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zi-Yu Li, M.D.</last_name>
      <email>ligregory369@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Zi-Yu Li, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital, the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pei-Wu Yu, M.D.,Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Pei-Wu Yu, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chang-Ming Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Li, M.D., Ph.D.</last_name>
      <email>liyong-lucky@21cn.com</email>
    </contact>
    <investigator>
      <last_name>Yong Li, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guo-Xin Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilonngjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kuan Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ze-Kuan Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Suo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi-Hong Sun, M.D., Ph.D.</last_name>
      <email>sun.yihong@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Yi-Hong Sun, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hua Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>RenJi Hospital, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gang Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai JiaoTong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lu Zang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xian-Li He, M.D.,Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Xian-Li He, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian-Kun Hu</last_name>
    </contact>
    <investigator>
      <last_name>Jian-Kun Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Chen P, Liu H, Zheng C, Liu F, Yu J, Li Z, Zhao G, Chen X, Wang K, Li P, Xing J, Li G. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. J Clin Oncol. 2016 Apr 20;34(12):1350-7. doi: 10.1200/JCO.2015.63.7215. Epub 2016 Feb 22.</citation>
    <PMID>26903580</PMID>
  </reference>
  <reference>
    <citation>Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010 Dec 10;28(35):5210-8. doi: 10.1200/JCO.2009.26.6114. Epub 2010 Nov 8.</citation>
    <PMID>21060024</PMID>
  </reference>
  <reference>
    <citation>Chen XZ, Yang K, Liu J, Chen XL, Hu JK. Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer. World J Gastroenterol. 2011 Oct 28;17(40):4542-4. doi: 10.3748/wjg.v17.i40.4542.</citation>
    <PMID>22110287</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 31, 2018</last_update_submitted>
  <last_update_submitted_qc>March 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Jian-Kun Hu</investigator_full_name>
    <investigator_title>Vice Director of Department of Gastrointestinal Surgery, West China Hospital</investigator_title>
  </responsible_party>
  <keyword>mortality</keyword>
  <keyword>morbidity</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>laparoscopic gastrectomy</keyword>
  <keyword>gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Pending</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

